Compare BioNTech SE - ADR (BNTX) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Schwab US Large Cap Growth ETF — how do they compare? BioNTech SE - ADR trades at $92.99 (market cap $23.31B), while Schwab US Large Cap Growth ETF trades at $35.62. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | SCHG | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | Sector/Thematic |
52-Week High | $119.34 | $35.83 |
52-Week Low | $83.89 | $28.10 |
Enterprise Value | $6.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
SCHG trades at $35.63, down 0.56% today, with a bullish technical outlook driven by strong moving average signals. The ETF's concentrated exposure to AI leaders like Nvidia and Microsoft positions it for growth, though high RSI readings suggest potential near-term consolidation. Recent news highlights institutional activity and the fund's low 0.04% expense ratio as key advantages.
The outlook remains positive given SCHG's alignment with AI infrastructure growth, but risks include heavy tech concentration and sensitivity to interest rates. Wall Street sentiment is mixed, with some analysts citing valuation concerns while others emphasize long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
